TD Private Client Wealth LLC Purchases 7,820 Shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC)

TD Private Client Wealth LLC increased its stake in GE HealthCare Technologies Inc. (NASDAQ:GEHC - Free Report) by 213.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 11,478 shares of the company's stock after purchasing an additional 7,820 shares during the period. TD Private Client Wealth LLC's holdings in GE HealthCare Technologies were worth $1,077,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of GEHC. Quent Capital LLC grew its holdings in shares of GE HealthCare Technologies by 18.4% during the 3rd quarter. Quent Capital LLC now owns 766 shares of the company's stock valued at $72,000 after purchasing an additional 119 shares during the last quarter. Greenleaf Trust grew its stake in shares of GE HealthCare Technologies by 1.7% during the third quarter. Greenleaf Trust now owns 7,619 shares of the company's stock valued at $715,000 after buying an additional 124 shares during the last quarter. EverSource Wealth Advisors LLC increased its holdings in shares of GE HealthCare Technologies by 8.7% in the second quarter. EverSource Wealth Advisors LLC now owns 1,590 shares of the company's stock worth $135,000 after buying an additional 127 shares during the period. Quarry LP lifted its stake in shares of GE HealthCare Technologies by 28.3% in the 2nd quarter. Quarry LP now owns 594 shares of the company's stock valued at $46,000 after acquiring an additional 131 shares during the last quarter. Finally, Harbour Investments Inc. grew its position in GE HealthCare Technologies by 4.3% during the 3rd quarter. Harbour Investments Inc. now owns 3,164 shares of the company's stock worth $297,000 after acquiring an additional 131 shares during the last quarter. 82.06% of the stock is owned by hedge funds and other institutional investors.

GE HealthCare Technologies Stock Down 0.6 %

Shares of NASDAQ GEHC traded down $0.53 during mid-day trading on Friday, hitting $81.10. 2,836,005 shares of the stock traded hands, compared to its average volume of 3,052,807. The company has a market cap of $37.05 billion, a price-to-earnings ratio of 22.28, a PEG ratio of 2.96 and a beta of 1.07. The stock has a fifty day moving average price of $85.84 and a 200-day moving average price of $83.71. GE HealthCare Technologies Inc. has a 52 week low of $71.31 and a 52 week high of $94.55. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.98 and a current ratio of 1.23.

GE HealthCare Technologies (NASDAQ:GEHC - Get Free Report) last announced its earnings results on Wednesday, October 30th. The company reported $1.14 EPS for the quarter, beating analysts' consensus estimates of $1.06 by $0.08. The firm had revenue of $4.86 billion for the quarter, compared to analysts' expectations of $4.87 billion. GE HealthCare Technologies had a net margin of 8.56% and a return on equity of 25.19%. The company's quarterly revenue was up .9% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.99 EPS. Research analysts anticipate that GE HealthCare Technologies Inc. will post 4.3 EPS for the current year.

GE HealthCare Technologies Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, February 14th. Shareholders of record on Tuesday, January 14th will be issued a $0.035 dividend. This represents a $0.14 annualized dividend and a yield of 0.17%. This is an increase from GE HealthCare Technologies's previous quarterly dividend of $0.03. The ex-dividend date is Tuesday, January 14th. GE HealthCare Technologies's payout ratio is 3.30%.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on GEHC. BTIG Research raised GE HealthCare Technologies from a "neutral" rating to a "buy" rating and set a $100.00 price objective for the company in a research note on Wednesday, September 18th. Stifel Nicolaus increased their price target on shares of GE HealthCare Technologies from $100.00 to $102.00 and gave the company a "buy" rating in a research report on Monday, September 30th. Wells Fargo & Company boosted their price objective on shares of GE HealthCare Technologies from $95.00 to $96.00 and gave the company an "overweight" rating in a research report on Thursday, October 31st. JPMorgan Chase & Co. assumed coverage on shares of GE HealthCare Technologies in a report on Monday, September 9th. They set a "neutral" rating and a $90.00 target price for the company. Finally, UBS Group downgraded GE HealthCare Technologies from a "neutral" rating to a "sell" rating and reduced their price target for the company from $84.00 to $74.00 in a report on Thursday, September 26th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $95.46.

Insider Transactions at GE HealthCare Technologies

In other GE HealthCare Technologies news, CEO Roland Rott sold 3,577 shares of the stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $86.48, for a total transaction of $309,338.96. Following the sale, the chief executive officer now directly owns 24,298 shares in the company, valued at approximately $2,101,291.04. This trade represents a 12.83 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.27% of the company's stock.

GE HealthCare Technologies Company Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.